+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Histone Deacetylase Inhibitors Market - Global Forecast 2026-2032- Product Image
Histone Deacetylase Inhibitors Market - Global Forecast 2026-2032- Product Image
Sale

Histone Deacetylase Inhibitors Market - Global Forecast 2026-2032

  • Report

  • 193 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 5532783
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Histone Deacetylase Inhibitors Market is projected to reach USD 1.44 Billion in 2026. It is expected to continue growing at a CAGR of 7.37%, reaching USD 2.21 Billion by 2032.

The histone deacetylase inhibitors market is anchored in the expanding role of epigenetic therapeutics across oncology, immunology, neurology, and rare disease research. HDAC inhibitors modulate chromatin structure and gene expression by blocking histone deacetylase enzymes, supporting tumor suppressor gene reactivation, cell-cycle arrest, apoptosis, and immune signaling. Clinically validated products such as vorinostat, romidepsin, belinostat, and panobinostat established the class in hematologic malignancies, while tucidinostat/chidamide demonstrates the importance of regional innovation in Asia.

Industry momentum is strongest where HDAC inhibitors are being repositioned from broad cytotoxic epigenetic agents to precision medicines supported by biomarkers, rational combinations, and improved isoform selectivity. Demand is shaped by persistent unmet needs in cutaneous T-cell lymphoma, peripheral T-cell lymphoma, multiple myeloma, acute myeloid leukemia, solid tumors, neurodegenerative disorders, and inflammatory conditions. For manufacturers, investors, and research organizations, competitive advantage increasingly depends on differentiated safety profiles, companion diagnostics, translational evidence, and clinical validation in defined patient populations.

Transformative Shifts in the HDAC Inhibitors Landscape

The HDAC inhibitors landscape is undergoing a shift from first-generation pan-HDAC inhibition toward selective and context-specific drug design. Earlier products proved clinical feasibility, particularly in T-cell lymphomas and hematologic cancers, but dose-limiting toxicities such as thrombocytopenia, gastrointestinal effects, fatigue, and cardiac monitoring requirements continue to influence adoption. This has accelerated interest in HDAC6, HDAC8, and class I-selective inhibitors that may improve tolerability while preserving therapeutic activity.

Combination strategies are also reshaping clinical and commercial opportunity. HDAC inhibitors are increasingly evaluated with immune checkpoint inhibitors, proteasome inhibitors, DNA methyltransferase inhibitors, targeted kinase inhibitors, hormonal therapy, and chemotherapy. The rationale is data-backed: epigenetic modulation can enhance antigen presentation, alter tumor microenvironment signaling, influence DNA damage response, and reverse resistance pathways. As a result, the market is moving away from single-agent expansion toward evidence-led combinations with measurable biomarkers and clearer therapeutic positioning.

Cumulative Impact of Artificial Intelligence on HDAC Inhibitors

Artificial intelligence is cumulatively improving HDAC inhibitor discovery by shortening hit identification, optimizing chemical structures, and predicting off-target liabilities before expensive wet-lab validation. AI-enabled structure-based modeling, generative chemistry, and multi-omics analysis help researchers prioritize compounds with improved isoform selectivity, blood-brain barrier potential, and pharmacokinetic properties. These capabilities are especially relevant for HDAC inhibitors because enzyme subtype selectivity strongly affects efficacy and safety.

AI is also strengthening clinical development. Machine learning models can integrate genomics, transcriptomics, proteomics, pathology images, electronic health records, and real-world evidence to identify patient subgroups more likely to respond to epigenetic therapy. In trial operations, AI supports site selection, enrollment planning, adverse event signal detection, and adaptive protocol design. The cumulative impact is a more efficient development pathway for histone deacetylase inhibitors and a higher probability of matching the right HDAC inhibitor combination to the right patient population.

Key Regional Insights Across Global HDAC Inhibitor Markets

Asia-Pacific is one of the most dynamic regions for histone deacetylase inhibitors because of strong oncology demand, large patient pools, expanding clinical trial capacity, and active domestic innovation. China has been particularly important through the development and approval of tucidinostat/chidamide, reinforcing the region’s role in epigenetic drug development. Japan, South Korea, Australia, and India contribute through mature oncology research networks, bioscience clusters, regulatory modernization, and growing participation in multinational trials.

North America remains the most established commercial and regulatory environment, led by the United States with multiple FDA-recognized HDAC inhibitor precedents and a dense ecosystem of biopharma sponsors, academic cancer centers, and precision oncology platforms. Canada adds value through clinical research infrastructure and public health technology assessment processes that influence evidence generation, reimbursement strategy, and specialty medicine adoption.

Europe offers a scientifically advanced but access-sensitive environment. The European Union’s centralized regulatory framework, strong cancer research networks, and emphasis on pharmacovigilance support high-quality evidence generation, while the United Kingdom, Germany, France, Italy, and Spain remain important markets for oncology trials and specialty care. Latin America, led by Brazil and Mexico, presents growth potential as oncology access improves, though reimbursement and infrastructure variability remain key constraints. The Middle East, especially GCC countries, is investing in specialty hospitals and genomics initiatives, while Africa represents a longer-term opportunity linked to oncology capacity building, diagnostics access, medicine availability, and clinical research inclusion.

Key Group Insights for HDAC Inhibitor Commercial Strategy

ASEAN is emerging as a meaningful growth corridor for HDAC inhibitors because rising cancer incidence, expanding private healthcare, and improving clinical trial participation are increasing demand for advanced oncology therapies. Countries such as Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines vary widely in reimbursement capacity and diagnostic infrastructure, making tiered access strategies, local partnerships, and physician education essential for sustainable adoption.

The GCC is investing heavily in oncology centers, genomic medicine, and specialty pharmaceutical access, creating opportunities for targeted therapies and biomarker-based treatment models. The European Union remains a high-value environment for HDAC inhibitor research because harmonized regulatory pathways, strong academic networks, cross-border oncology collaborations, and structured pharmacovigilance enable rigorous development and post-authorization evidence generation.

BRICS countries collectively represent a large patient base, expanding clinical research activity, and growing pharmaceutical manufacturing capability, with China and India central to clinical development, active ingredient production, and cost-sensitive access models. The G7 continues to set standards for regulatory science, intellectual property protection, pricing scrutiny, oncology guideline adoption, and clinical evidence requirements. NATO member markets overlap substantially with advanced North American and European health systems, supporting resilient supply chains, research collaboration, secure manufacturing networks, and oncology preparedness.

Key Country Insights for Histone Deacetylase Inhibitors

The United States is the leading country environment for histone deacetylase inhibitors due to FDA regulatory precedent, strong oncology reimbursement pathways, high clinical trial density, and robust venture-backed biotech activity. Canada supports evidence-driven adoption through academic oncology networks and structured health technology assessment. Mexico and Brazil are the most relevant Latin American markets in this country set, with Brazil offering scale and domestic clinical research capability, while Mexico benefits from proximity to U.S. sponsors and improving specialty care access.

In Europe, the United Kingdom, Germany, France, Italy, and Spain are central to HDAC inhibitor development and commercialization. Germany and France offer strong academic medicine, cancer care infrastructure, and reimbursement influence; the United Kingdom contributes translational research and early-phase trial expertise; and Italy and Spain provide important hematology and oncology trial networks. Russia retains scientific capability, although geopolitical conditions, regulatory divergence, and supply-chain factors can complicate multinational engagement.

In Asia-Pacific, China is a major driver because of domestic HDAC inhibitor innovation, large oncology populations, and expanding regulatory modernization. India offers manufacturing strength, a growing clinical research base, and high unmet need across oncology and inflammatory diseases. Japan provides advanced oncology infrastructure and a sophisticated regulatory environment, while South Korea is recognized for rapid trial execution, biopharma innovation, and digital health integration. Australia remains important for early-phase oncology studies, strong ethics standards, and globally connected research hospitals.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize selective HDAC inhibitor pipelines, biomarker-led development, and rational combination strategies rather than relying on broad class effects. Differentiation should be built around isoform selectivity, durable response, tolerability, drug-drug interaction management, and convenience of administration. Sponsors should also invest early in companion diagnostic strategies, translational endpoints, pharmacodynamic markers, and real-world evidence plans to support payer confidence.

Commercial teams should align regional access models with local oncology infrastructure. In mature markets, value dossiers must demonstrate incremental benefit over established regimens and clarify patient selection. In emerging markets, partnerships with cancer centers, local manufacturers, contract research networks, and diagnostic providers can improve affordability and adoption. Across all regions, leaders should strengthen pharmacovigilance, supply chain resilience, regulatory intelligence, and AI-enabled competitive monitoring to track rapidly evolving epigenetic therapy pipelines.

Research Methodology for HDAC Inhibitor Market Insights

This executive summary is developed using a structured research methodology that integrates regulatory intelligence, peer-reviewed scientific literature, clinical trial registry analysis, pipeline assessment, treatment guideline review, and secondary validation from recognized oncology and pharmaceutical sources. The analysis emphasizes verified information on approved HDAC inhibitors, clinical development trends, regional healthcare capabilities, safety considerations, and evidence-based therapeutic positioning.

The methodology combines qualitative expert interpretation with data-backed triangulation across product approvals, trial activity, disease burden indicators, reimbursement environments, regional innovation capacity, and healthcare infrastructure. Insights are assessed through segmentation by geography, therapeutic application, mechanism selectivity, development stage, and commercialization readiness.

Conclusion: Future Direction for Histone Deacetylase Inhibitors

The histone deacetylase inhibitors market is evolving from a niche oncology class into a broader epigenetic therapeutics platform shaped by precision medicine, AI-enabled discovery, and combination-based clinical strategies. Established approvals validate the mechanism, while next-generation selective inhibitors and biomarker-driven trials are redefining the pathway to differentiated value.

Future progress will depend on the ability of developers to demonstrate clear clinical benefit, manage toxicity, identify responsive patient populations, and secure reimbursement in increasingly evidence-driven health systems. Organizations that integrate translational science, artificial intelligence, regional access planning, and disciplined clinical execution will be best positioned to lead the next phase of the HDAC inhibitors market.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Histone Deacetylase Inhibitors Market, by Drug Class
7.1. Introduction
7.2. Isoform-Selective HDAC Inhibitors
7.2.1. Class I
7.2.1.1. HDAC1 Inhibitors
7.2.1.2. HDAC2 Inhibitors
7.2.1.3. HDAC3 Inhibitors
7.2.1.4. HDAC8 Inhibitors
7.2.2. Class II
7.2.2.1. HDAC4 Inhibitors
7.2.2.2. HDAC5 Inhibitors
7.2.2.3. HDAC6 Inhibitors
7.2.2.4. HDAC7 Inhibitors
7.2.3. Class III
7.2.3.1. Sirtuin1 Inhibitors
7.2.3.2. Sirtuin2 Inhibitors
7.2.3.3. Sirtuin3 Inhibitors
7.2.4. Class IV
7.3. Pan-HDAC Inhibitors
8. Histone Deacetylase Inhibitors Market, by Route of Administration
8.1. Introduction
8.2. Intravenous (IV)
8.3. Oral
9. Histone Deacetylase Inhibitors Market, by Distribution Channel
9.1. Introduction
9.2. Hospital Pharmacy
9.3. Online Pharmacy
9.4. Retail Pharmacy
10. Histone Deacetylase Inhibitors Market, by Therapeutic Indication
10.1. Introduction
10.2. Cancer
10.2.1. Hematological Cancers
10.2.1.1. Leukemia
10.2.1.2. Lymphoma
10.2.1.3. Multiple Myeloma
10.2.2. Solid Tumors
10.2.2.1. Breast Cancer
10.2.2.2. Lung Cancer
10.2.2.3. Prostate Cancer
10.3. Inflammatory Disorders
10.3.1. Inflammatory Bowel Disease
10.3.2. Rheumatoid Arthritis
10.4. Neurological Disorders
10.4.1. Alzheimer's Disease
10.4.2. Parkinson's Disease
11. Histone Deacetylase Inhibitors Market, by End User
11.1. Introduction
11.2. Clinics
11.3. Hospitals
11.4. Research Institutes
12. Histone Deacetylase Inhibitors Market, by Region
12.1. Asia-Pacific
12.2. Europe
12.3. North America
12.4. Latin America
12.5. Africa
12.6. Middle East
13. Histone Deacetylase Inhibitors Market, by Group
13.1. NATO
13.2. G7
13.3. European Union
13.4. BRICS
13.5. ASEAN
13.6. GCC
14. Histone Deacetylase Inhibitors Market, by Country
14.1. United States
14.2. China
14.3. Germany
14.4. Canada
14.5. Japan
14.6. India
14.7. United Kingdom
14.8. Brazil
14.9. Mexico
14.10. France
14.11. Italy
14.12. Australia
14.13. South Korea
14.14. Russia
14.15. Spain
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. FPNV Positioning Matrix, 2025
15.3. Market Concentration Analysis, 2025
15.3.1. Concentration Ratio (CR)
15.3.2. Herfindahl Hirschman Index (HHI)
15.4. Recent Developments & Impact Analysis, 2025
15.5. Product Portfolio Analysis, 2025
15.6. Benchmarking Analysis, 2025
16. Company Profiles
16.1. AstraZeneca plc
16.2. Bio-Techne Corporation
16.3. Bristol-Myers Squibb Company
16.4. Curis Inc.
16.5. Eisai Co. Ltd.
16.6. Huya Bioscience International LLC
16.7. Italfarmaco S.p.A.
16.8. Karyopharm Therapeutics Inc.
16.9. Medivir AB
16.10. MEI Pharma Inc.
16.11. Merck KGaA
16.12. Novartis AG
16.13. Shenzhen Chipscreen Biosciences Co., Ltd.
16.14. Shuttle Pharmaceuticals Holdings, Inc.
16.15. Syndax Pharmaceuticals Inc.
16.16. Thermo Fisher Scientific, Inc.
16.17. Tokyo Chemical Industry Pvt. Ltd.
16.18. Xynomic Pharmaceuticals Co., Ltd.
List of Figures
FIGURE 1. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
FIGURE 7. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 9. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 11. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY THERAPEUTIC INDICATION, 2025 VS 2032 (%)
FIGURE 13. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY THERAPEUTIC INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 15. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 17. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 19. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 21. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 23. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL ISOFORM-SELECTIVE HDAC INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL ISOFORM-SELECTIVE HDAC INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL ISOFORM-SELECTIVE HDAC INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL CLASS I MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL CLASS I MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL CLASS I MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL HDAC1 INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL HDAC1 INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL HDAC1 INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL HDAC2 INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL HDAC2 INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL HDAC2 INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL HDAC3 INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL HDAC3 INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL HDAC3 INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL HDAC8 INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL HDAC8 INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL HDAC8 INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL CLASS II MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL CLASS II MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL CLASS II MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL HDAC4 INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL HDAC4 INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL HDAC4 INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL HDAC5 INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL HDAC5 INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL HDAC5 INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL HDAC6 INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL HDAC6 INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL HDAC6 INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL HDAC7 INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL HDAC7 INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL HDAC7 INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL CLASS III MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL CLASS III MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL CLASS III MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL SIRTUIN1 INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL SIRTUIN1 INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL SIRTUIN1 INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL SIRTUIN2 INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL SIRTUIN2 INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL SIRTUIN2 INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL SIRTUIN3 INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL SIRTUIN3 INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL SIRTUIN3 INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL CLASS IV MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL CLASS IV MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL CLASS IV MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL PAN-HDAC INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL PAN-HDAC INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL PAN-HDAC INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL INTRAVENOUS (IV) MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL INTRAVENOUS (IV) MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL INTRAVENOUS (IV) MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL ORAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL ORAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL ONLINE PHARMACY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL ONLINE PHARMACY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL ONLINE PHARMACY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL RETAIL PHARMACY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL RETAIL PHARMACY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL RETAIL PHARMACY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY THERAPEUTIC INDICATION, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL CANCER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL CANCER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL CANCER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL HEMATOLOGICAL CANCERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL HEMATOLOGICAL CANCERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL HEMATOLOGICAL CANCERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL LEUKEMIA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL LEUKEMIA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL LEUKEMIA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL LYMPHOMA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL LYMPHOMA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL LYMPHOMA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL MULTIPLE MYELOMA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL MULTIPLE MYELOMA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL MULTIPLE MYELOMA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL SOLID TUMORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL SOLID TUMORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL SOLID TUMORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL BREAST CANCER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL BREAST CANCER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL BREAST CANCER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL LUNG CANCER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL LUNG CANCER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL LUNG CANCER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL PROSTATE CANCER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL PROSTATE CANCER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL PROSTATE CANCER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL INFLAMMATORY DISORDERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL INFLAMMATORY DISORDERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 102. GLOBAL INFLAMMATORY DISORDERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 103. GLOBAL INFLAMMATORY BOWEL DISEASE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 104. GLOBAL INFLAMMATORY BOWEL DISEASE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 105. GLOBAL INFLAMMATORY BOWEL DISEASE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 106. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 107. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 108. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 109. GLOBAL NEUROLOGICAL DISORDERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 110. GLOBAL NEUROLOGICAL DISORDERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 111. GLOBAL NEUROLOGICAL DISORDERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 112. GLOBAL ALZHEIMER'S DISEASE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 113. GLOBAL ALZHEIMER'S DISEASE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 114. GLOBAL ALZHEIMER'S DISEASE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 115. GLOBAL PARKINSON'S DISEASE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 116. GLOBAL PARKINSON'S DISEASE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 117. GLOBAL PARKINSON'S DISEASE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 118. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 119. GLOBAL CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 120. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 121. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 122. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 123. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 124. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 125. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 126. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 127. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 128. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 129. ASIA-PACIFIC HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 130. ASIA-PACIFIC HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 131. ASIA-PACIFIC HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY ISOFORM-SELECTIVE HDAC INHIBITORS, 2017-2032 (USD MILLION)
TABLE 132. ASIA-PACIFIC HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS I, 2017-2032 (USD MILLION)
TABLE 133. ASIA-PACIFIC HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS II, 2017-2032 (USD MILLION)
TABLE 134. ASIA-PACIFIC HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS III, 2017-2032 (USD MILLION)
TABLE 135. ASIA-PACIFIC HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 136. ASIA-PACIFIC HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 137. ASIA-PACIFIC HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY THERAPEUTIC INDICATION, 2017-2032 (USD MILLION)
TABLE 138. ASIA-PACIFIC HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CANCER, 2017-2032 (USD MILLION)
TABLE 139. ASIA-PACIFIC HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2017-2032 (USD MILLION)
TABLE 140. ASIA-PACIFIC HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 141. ASIA-PACIFIC HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY INFLAMMATORY DISORDERS, 2017-2032 (USD MILLION)
TABLE 142. ASIA-PACIFIC HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2017-2032 (USD MILLION)
TABLE 143. ASIA-PACIFIC HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 144. EUROPE HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 145. EUROPE HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 146. EUROPE HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY ISOFORM-SELECTIVE HDAC INHIBITORS, 2017-2032 (USD MILLION)
TABLE 147. EUROPE HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS I, 2017-2032 (USD MILLION)
TABLE 148. EUROPE HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS II, 2017-2032 (USD MILLION)
TABLE 149. EUROPE HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS III, 2017-2032 (USD MILLION)
TABLE 150. EUROPE HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 151. EUROPE HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 152. EUROPE HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY THERAPEUTIC INDICATION, 2017-2032 (USD MILLION)
TABLE 153. EUROPE HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CANCER, 2017-2032 (USD MILLION)
TABLE 154. EUROPE HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2017-2032 (USD MILLION)
TABLE 155. EUROPE HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 156. EUROPE HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY INFLAMMATORY DISORDERS, 2017-2032 (USD MILLION)
TABLE 157. EUROPE HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2017-2032 (USD MILLION)
TABLE 158. EUROPE HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 159. NORTH AMERICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 160. NORTH AMERICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 161. NORTH AMERICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY ISOFORM-SELECTIVE HDAC INHIBITORS, 2017-2032 (USD MILLION)
TABLE 162. NORTH AMERICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS I, 2017-2032 (USD MILLION)
TABLE 163. NORTH AMERICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS II, 2017-2032 (USD MILLION)
TABLE 164. NORTH AMERICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS III, 2017-2032 (USD MILLION)
TABLE 165. NORTH AMERICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 166. NORTH AMERICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 167. NORTH AMERICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY THERAPEUTIC INDICATION, 2017-2032 (USD MILLION)
TABLE 168. NORTH AMERICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CANCER, 2017-2032 (USD MILLION)
TABLE 169. NORTH AMERICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2017-2032 (USD MILLION)
TABLE 170. NORTH AMERICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 171. NORTH AMERICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY INFLAMMATORY DISORDERS, 2017-2032 (USD MILLION)
TABLE 172. NORTH AMERICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2017-2032 (USD MILLION)
TABLE 173. NORTH AMERICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 174. LATIN AMERICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 175. LATIN AMERICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 176. LATIN AMERICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY ISOFORM-SELECTIVE HDAC INHIBITORS, 2017-2032 (USD MILLION)
TABLE 177. LATIN AMERICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS I, 2017-2032 (USD MILLION)
TABLE 178. LATIN AMERICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS II, 2017-2032 (USD MILLION)
TABLE 179. LATIN AMERICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS III, 2017-2032 (USD MILLION)
TABLE 180. LATIN AMERICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 181. LATIN AMERICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 182. LATIN AMERICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY THERAPEUTIC INDICATION, 2017-2032 (USD MILLION)
TABLE 183. LATIN AMERICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CANCER, 2017-2032 (USD MILLION)
TABLE 184. LATIN AMERICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2017-2032 (USD MILLION)
TABLE 185. LATIN AMERICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 186. LATIN AMERICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY INFLAMMATORY DISORDERS, 2017-2032 (USD MILLION)
TABLE 187. LATIN AMERICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2017-2032 (USD MILLION)
TABLE 188. LATIN AMERICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 189. AFRICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 190. AFRICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 191. AFRICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY ISOFORM-SELECTIVE HDAC INHIBITORS, 2017-2032 (USD MILLION)
TABLE 192. AFRICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS I, 2017-2032 (USD MILLION)
TABLE 193. AFRICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS II, 2017-2032 (USD MILLION)
TABLE 194. AFRICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS III, 2017-2032 (USD MILLION)
TABLE 195. AFRICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 196. AFRICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 197. AFRICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY THERAPEUTIC INDICATION, 2017-2032 (USD MILLION)
TABLE 198. AFRICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CANCER, 2017-2032 (USD MILLION)
TABLE 199. AFRICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2017-2032 (USD MILLION)
TABLE 200. AFRICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 201. AFRICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY INFLAMMATORY DISORDERS, 2017-2032 (USD MILLION)
TABLE 202. AFRICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2017-2032 (USD MILLION)
TABLE 203. AFRICA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 204. MIDDLE EAST HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 205. MIDDLE EAST HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 206. MIDDLE EAST HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY ISOFORM-SELECTIVE HDAC INHIBITORS, 2017-2032 (USD MILLION)
TABLE 207. MIDDLE EAST HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS I, 2017-2032 (USD MILLION)
TABLE 208. MIDDLE EAST HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS II, 2017-2032 (USD MILLION)
TABLE 209. MIDDLE EAST HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS III, 2017-2032 (USD MILLION)
TABLE 210. MIDDLE EAST HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 211. MIDDLE EAST HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 212. MIDDLE EAST HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY THERAPEUTIC INDICATION, 2017-2032 (USD MILLION)
TABLE 213. MIDDLE EAST HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CANCER, 2017-2032 (USD MILLION)
TABLE 214. MIDDLE EAST HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2017-2032 (USD MILLION)
TABLE 215. MIDDLE EAST HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 216. MIDDLE EAST HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY INFLAMMATORY DISORDERS, 2017-2032 (USD MILLION)
TABLE 217. MIDDLE EAST HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2017-2032 (USD MILLION)
TABLE 218. MIDDLE EAST HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 219. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 220. NATO HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 221. NATO HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 222. NATO HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY ISOFORM-SELECTIVE HDAC INHIBITORS, 2017-2032 (USD MILLION)
TABLE 223. NATO HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS I, 2017-2032 (USD MILLION)
TABLE 224. NATO HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS II, 2017-2032 (USD MILLION)
TABLE 225. NATO HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS III, 2017-2032 (USD MILLION)
TABLE 226. NATO HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 227. NATO HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 228. NATO HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY THERAPEUTIC INDICATION, 2017-2032 (USD MILLION)
TABLE 229. NATO HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CANCER, 2017-2032 (USD MILLION)
TABLE 230. NATO HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2017-2032 (USD MILLION)
TABLE 231. NATO HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 232. NATO HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY INFLAMMATORY DISORDERS, 2017-2032 (USD MILLION)
TABLE 233. NATO HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2017-2032 (USD MILLION)
TABLE 234. NATO HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 235. G7 HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 236. G7 HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 237. G7 HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY ISOFORM-SELECTIVE HDAC INHIBITORS, 2017-2032 (USD MILLION)
TABLE 238. G7 HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS I, 2017-2032 (USD MILLION)
TABLE 239. G7 HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS II, 2017-2032 (USD MILLION)
TABLE 240. G7 HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS III, 2017-2032 (USD MILLION)
TABLE 241. G7 HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 242. G7 HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 243. G7 HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY THERAPEUTIC INDICATION, 2017-2032 (USD MILLION)
TABLE 244. G7 HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CANCER, 2017-2032 (USD MILLION)
TABLE 245. G7 HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2017-2032 (USD MILLION)
TABLE 246. G7 HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 247. G7 HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY INFLAMMATORY DISORDERS, 2017-2032 (USD MILLION)
TABLE 248. G7 HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2017-2032 (USD MILLION)
TABLE 249. G7 HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 250. EUROPEAN UNION HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 251. EUROPEAN UNION HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 252. EUROPEAN UNION HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY ISOFORM-SELECTIVE HDAC INHIBITORS, 2017-2032 (USD MILLION)
TABLE 253. EUROPEAN UNION HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS I, 2017-2032 (USD MILLION)
TABLE 254. EUROPEAN UNION HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS II, 2017-2032 (USD MILLION)
TABLE 255. EUROPEAN UNION HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS III, 2017-2032 (USD MILLION)
TABLE 256. EUROPEAN UNION HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 257. EUROPEAN UNION HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 258. EUROPEAN UNION HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY THERAPEUTIC INDICATION, 2017-2032 (USD MILLION)
TABLE 259. EUROPEAN UNION HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CANCER, 2017-2032 (USD MILLION)
TABLE 260. EUROPEAN UNION HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2017-2032 (USD MILLION)
TABLE 261. EUROPEAN UNION HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 262. EUROPEAN UNION HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY INFLAMMATORY DISORDERS, 2017-2032 (USD MILLION)
TABLE 263. EUROPEAN UNION HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2017-2032 (USD MILLION)
TABLE 264. EUROPEAN UNION HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 265. BRICS HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 266. BRICS HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 267. BRICS HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY ISOFORM-SELECTIVE HDAC INHIBITORS, 2017-2032 (USD MILLION)
TABLE 268. BRICS HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS I, 2017-2032 (USD MILLION)
TABLE 269. BRICS HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS II, 2017-2032 (USD MILLION)
TABLE 270. BRICS HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS III, 2017-2032 (USD MILLION)
TABLE 271. BRICS HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 272. BRICS HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 273. BRICS HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY THERAPEUTIC INDICATION, 2017-2032 (USD MILLION)
TABLE 274. BRICS HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CANCER, 2017-2032 (USD MILLION)
TABLE 275. BRICS HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2017-2032 (USD MILLION)
TABLE 276. BRICS HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 277. BRICS HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY INFLAMMATORY DISORDERS, 2017-2032 (USD MILLION)
TABLE 278. BRICS HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2017-2032 (USD MILLION)
TABLE 279. BRICS HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 280. ASEAN HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 281. ASEAN HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 282. ASEAN HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY ISOFORM-SELECTIVE HDAC INHIBITORS, 2017-2032 (USD MILLION)
TABLE 283. ASEAN HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS I, 2017-2032 (USD MILLION)
TABLE 284. ASEAN HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS II, 2017-2032 (USD MILLION)
TABLE 285. ASEAN HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS III, 2017-2032 (USD MILLION)
TABLE 286. ASEAN HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 287. ASEAN HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 288. ASEAN HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY THERAPEUTIC INDICATION, 2017-2032 (USD MILLION)
TABLE 289. ASEAN HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CANCER, 2017-2032 (USD MILLION)
TABLE 290. ASEAN HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2017-2032 (USD MILLION)
TABLE 291. ASEAN HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 292. ASEAN HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY INFLAMMATORY DISORDERS, 2017-2032 (USD MILLION)
TABLE 293. ASEAN HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2017-2032 (USD MILLION)
TABLE 294. ASEAN HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 295. GCC HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 296. GCC HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 297. GCC HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY ISOFORM-SELECTIVE HDAC INHIBITORS, 2017-2032 (USD MILLION)
TABLE 298. GCC HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS I, 2017-2032 (USD MILLION)
TABLE 299. GCC HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS II, 2017-2032 (USD MILLION)
TABLE 300. GCC HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS III, 2017-2032 (USD MILLION)
TABLE 301. GCC HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 302. GCC HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 303. GCC HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY THERAPEUTIC INDICATION, 2017-2032 (USD MILLION)
TABLE 304. GCC HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CANCER, 2017-2032 (USD MILLION)
TABLE 305. GCC HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2017-2032 (USD MILLION)
TABLE 306. GCC HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 307. GCC HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY INFLAMMATORY DISORDERS, 2017-2032 (USD MILLION)
TABLE 308. GCC HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2017-2032 (USD MILLION)
TABLE 309. GCC HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 310. GLOBAL HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 311. UNITED STATES HISTONE DEACETYLASE INHIBITORS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 312. UNITED STATES HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 313. UNITED STATES HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY ISOFORM-SELECTIVE HDAC INHIBITORS, 2017-2032 (USD MILLION)
TABLE 314. UNITED STATES HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS I, 2017-2032 (USD MILLION)
TABLE 315. UNITED STATES HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS II, 2017-2032 (USD MILLION)
TABLE 316. UNITED STATES HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS III, 2017-2032 (USD MILLION)
TABLE 317. UNITED STATES HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 318. UNITED STATES HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 319. UNITED STATES HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY THERAPEUTIC INDICATION, 2017-2032 (USD MILLION)
TABLE 320. UNITED STATES HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CANCER, 2017-2032 (USD MILLION)
TABLE 321. UNITED STATES HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2017-2032 (USD MILLION)
TABLE 322. UNITED STATES HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY SOLID TUMORS, 2017-2032 (USD MILLION)
TABLE 323. UNITED STATES HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY INFLAMMATORY DISORDERS, 2017-2032 (USD MILLION)
TABLE 324. UNITED STATES HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2017-2032 (USD MILLION)
TABLE 325. UNITED STATES HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 326. CHINA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 327. CHINA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 328. CHINA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY ISOFORM-SELECTIVE HDAC INHIBITORS, 2017-2032 (USD MILLION)
TABLE 329. CHINA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS I, 2017-2032 (USD MILLION)
TABLE 330. CHINA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS II, 2017-2032 (USD MILLION)
TABLE 331. CHINA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY CLASS III, 2017-2032 (USD MILLION)
TABLE 332. CHINA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 333. CHINA HISTONE DEACETYLASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 334. CHINA HISTONE DEACETYLASE INHIBITOR

Companies Mentioned

  • AstraZeneca plc
  • Bio-Techne Corporation
  • Bristol‑Myers Squibb Company
  • Curis Inc.
  • Eisai Co. Ltd.
  • Huya Bioscience International LLC
  • Italfarmaco S.p.A.
  • Karyopharm Therapeutics Inc.
  • Medivir AB
  • MEI Pharma Inc.
  • Merck KGaA
  • Novartis AG
  • Shenzhen Chipscreen Biosciences Co., Ltd.
  • Shuttle Pharmaceuticals Holdings, Inc.
  • Syndax Pharmaceuticals Inc.
  • Thermo Fisher Scientific, Inc.
  • Tokyo Chemical Industry Pvt. Ltd.
  • Xynomic Pharmaceuticals Co., Ltd.

Table Information

Report AttributeDetails
No. of Pages193
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 1.44 Billion
Forecasted Market Value ( USD ) by 2032 $ 2.21 Billion
Compound Annual Growth Rate7.3%
Regions CoveredGlobal
No. of Companies Mentioned18

Related Topics

Related Reports

Histone Deacetylase Inhibitors Market Report 2026 - Product Image

Histone Deacetylase Inhibitors Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Histone Deacetylase Inhibitors Market Insights, Analysis and Forecast 2026-2031 - Product Image

Histone Deacetylase Inhibitors Market Insights, Analysis and Forecast 2026-2031

  • Report
  • 86 Pages
  • Global
From
Histone Deacetylase (HDAC) Inhibitors Market Report 2026 - Product Image

Histone Deacetylase (HDAC) Inhibitors Market Report 2026

  • Report
  • 250 Pages
  • Global
From
HDAC Inhibitors - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031) - Product Image

HDAC Inhibitors - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • Report
  • 120 Pages
  • Global
From
Histone Deacetylases in Neurodegenerative Disease Part A. Methods in Enzymology Volume 733 - Product Image

Histone Deacetylases in Neurodegenerative Disease Part A. Methods in Enzymology Volume 733

  • Book

About the Histone Deacetylase Inhibitor Market

Histone Deacetylase Inhibitors (HDACIs) are a class of drugs used to treat diseases of the Central Nervous System (CNS). HDACIs are used to treat a variety of neurological disorders, including Alzheimer's disease, Parkinson's disease, Huntington's disease, and multiple sclerosis. HDACIs work by blocking the activity of histone deacetylases, enzymes that regulate gene expression. By blocking these enzymes, HDACIs can reduce inflammation and improve cognitive function. HDACIs are a relatively new class of drugs, and the market is still in its early stages. However, the potential of HDACIs to treat a variety of neurological disorders has attracted the attention of many pharmaceutical companies. Several companies are currently developing HDACIs for the treatment of CNS diseases, including Merck, Pfizer, Novartis, and AstraZeneca. Additionally, several biotechnology companies are researching HDACIs for the treatment of neurological disorders, including AbbVie, Biogen, and Genentech. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.